



(51) International Patent Classification:

C07D 213/64 (2006.01) *C07D 417/12* (2006.01)
C07D 213/69 (2006.01) *A61P 31/00* (2006.01)
C07D 401/04 (2006.01) *A61K 31/4412* (2006.01)
C07D 401/10 (2006.01) *A61K 31/4427* (2006.01)
C07D 405/04 (2006.01) *A61K 31/4439* (2006.01)
C07D 405/12 (2006.01) *A61K 31/4433* (2006.01)
C07D 413/10 (2006.01)

(21) International Application Number:

PCT/IB2012/050812

(22) International Filing Date:

22 February 2012 (22.02.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/449,825 7 March 2011 (07.03.2011) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BROWN, Mathew Frank** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **CHE, Ye** [CN/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **MELNICK, Michael Joseph** [US/US]; 7159 Hickory Point Drive, Portage, Michigan 49024 (US). **MONTGOMERY, Justin Ian** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **PLUMMER, Mark Stephen** [US/US]; 6 Halls Road, Westbrook, Connecticut 06498 (US). **PRICE, Loren Michael** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **REILLY, Usa** [GB/US];

Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US).

(74) Agent: **BENSON, Gregg C.**; Eastern Point Road, MS 8260-2141, Groton, Connecticut 06340 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: FLUORO-PYRIDINONE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS

(57) Abstract: The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.

